TACT2 will enroll about 1200 patients in the U.S. and Canada who are 50 years of age or older, have had a heart attack, have diabetes, and meet other eligibility criteria.
Click on a map marker to see more information about the sites that are participating in TACT2.
Where can I learn more about TACT2?
Learn more about the study at clinicaltrials.gov
The chelation therapy used in the TACT2 study consists of up to 40 treatments through a vein in your arm (infusion) of a solution of disodium ethylene diamine tetra-acetic acid (Na2EDTA or disodium EDTA), vitamins, and other dissolved materials. Disodium EDTA is thought to bind toxic metals in the body, including lead and cadmium, that may contribute to the development of heart disease.
Although the U.S. Food and Drug Administration (FDA) has not approved disodium EDTA chelation therapy as an effective treatment for heart disease, chelation therapy has been practiced in the community for many years. The drug used in this study, disodium EDTA, is not the same drug approved by the FDA for use in cases of lead poisoning. The present clinical practice of chelation therapy also involves the use of high-dose antioxidant vitamins, minerals, and nutritional supplements taken by mouth.